(EMAILWIRE.COM, March 20, 2002 ) Samaritan Pharmaceuticals, Inc. (OTC/BB: SPHC) Dr. Janet Greeson, CEO of Samaritan, has announced favorable results in developing innovative drug candidates and charts Samaritan's technology pipeline.

Dr. Greeson stated, "The promise of Samaritan is predicated on generating products to commercialize. Our technologies are based on the insights, intuition and creativity of our scientists at Samaritan Research Laboratories, Georgetown University Medical Center. We believe this collaboration fosters scientific creativity in which a number of promising drug candidates can move forward more quickly and hopefully decrease the average travel time from lab to patients." She further stated, "Our intention is to license these drug candidates to major pharmaceutical companies and in certain disease categories, we may process our drug candidates through all of the FDA required human clinical trials."

About Samaritan Pharmaceuticals:

Samaritan Pharmaceuticals is a Biopharmaceutical company dedicated to saving lives by focusing on breakthrough discovery for Aging Related Disorders, Alzheimer's, Cancer, High Cholesterol, HIV and Parkinson's. Our technology is based on the mechanisms underlying Cholesterol biosynthesis, metabolism, transport, compartmentalization, and its actions. Samaritan hopes to achieve a competitive position in biotech with a robust "pipeline" of patents and technology surrounding Cholesterol. For more information visit: www.samaritanpharmaceuticals.com.

The company disclaims any information that is created by an outside party and endorses only information that is communicated by its press releases, filings and website. This news release contains forward-looking statements that reflect management's current beliefs about the potential for its drug candidates, science and technology for the approved indications. However, as with any biopharmaceutical under development, there are significant risks and uncertainties in the process of development and regulatory review. There are no guarantees that the product will prove to be commercially successful. For additional information about the factors that affect the company's business, please see Exhibit 99 to the company's latest Form 10-Q, filed November 2001. The company undertakes no duty to update forward-looking statements.

For More Info Contact: Samaritan Pharmaceuticals Inc. 702-735-7001, Fax 702-737-7016
Website: www.samaritanpharmaceuticals.com


---------------

Produced for Samaritan Pharmaceuticals

Contacts:

Gene Boyle
Business Dev.
GeneBoyle@aol.com

Doug Bessert
Investor Relations
DougBessert@aol.com

---------------

Contact Information:
Samaritan Pharmaceuticals
Joseph Nchor
Tel:
Email us


This is a press release. Press release distribution and press release services by EmailWire.Com: http://www.emailwire.com/us-press-release-distribution.php.